Olaratumab + Doxorubicin for Metastatic Soft-Tissue Sarcoma
1 Visualizzazioni
• 07/18/23
0
0
Incorporare
administrator
Iscritti
William D. Tap, MD; Richard F. Riedel, MD; Victor M. Villalobos, MD, PhD; and Kristen N. Ganjoo, MD, comment on the overall survival benefit seen in the phase II study of doxorubicin and olaratumab, the phase III ANNOUNCE trial, and patient selection for this regimen and data for other regimens.
Mostra di più
Commenti su Facebook
SORT BY-
I migliori commenti
-
Ultimi commenti